On July 29, 2026, Femtech Insider reported that Kompass Diagnostics has entered an exclusive licensing agreement with the University of Chicago to commercialize a rapid finger-prick hormone testing platform for fertility care. The pitch is speed: high-sensitivity silicon biosensors reading blood-based biomarkers and returning results in roughly ten minutes, at the point of care, instead of sending samples to a centralized lab.

Why It Matters

Hormone measurement is quietly becoming the most contested layer in femtech. In the last two weeks alone, University of Edinburgh spinout Kahu SiliconBio took a £1.2M grant from Germany's SPRIN-D to build a *continuous* hormone biosensor, and Natural Cycles landed its sixth FDA clearance for an algorithm that infers fertile windows without drawing blood at all. Three distinct bets on the same underlying question: how do you know what someone's hormones are doing right now, cheaply enough to act on it? Kompass's answer is the least glamorous and possibly the most immediately commercial — it does not require consumer behavior change, a subscription, or regulatory novelty. It sells into an existing clinical workflow with an existing budget line, replacing lab send-outs. That is a B2B diagnostics business wearing femtech clothing, and it competes with entrenched central-lab economics rather than with other apps. The obvious caveat: a licensing agreement is not a cleared product. Femtech Insider's report does not detail FDA regulatory status for the panels, and hormone assays used to guide IVF dosing sit in a different risk conversation than a wellness-adjacent at-home kit. The relevant diligence questions are clearance pathway, analytical validation against central-lab reference standards, and whether ten-minute results are precise enough for the dosing decisions clinics would actually use them for. Worth watching alongside the broader access story — the same week ABC raised $4M on a promise of $8,995 IVF, the cost stack that makes that math work runs straight through diagnostics like this one.

The company currently offers four testing panels designed around IVF and egg-freezing protocols, measuring estradiol, progesterone and multiple thyroid markers. Per Kompass's own materials, the analyzer takes a 10-microlitre whole-blood sample applied to a test cartridge, supports both venous and capillary draws, and calibrates the cartridge before each run — an on-screen guide is meant to let staff with minimal laboratory training perform the analysis. Kompass has raised $2.7 million to date and says the licensing deal will fund further platform development and expansion into additional diagnostic applications.

The problem being solved is genuinely operational. Fertility clinics running stimulation cycles need same-day hormone readings to adjust dosing, and today that means either a relationship with a centralized lab (slow, and it forces extra patient visits) or expensive in-house lab infrastructure (a capital barrier for smaller practices and OB-GYN offices). Kompass's argument is that point-of-care testing eliminates the extra visit, compresses the decision loop, and lowers the cost floor for offering fertility monitoring at all.

Sources

Update — 2026-08-02

Initial entry — story first created.